A.ö. Krankenhaus der Barmherzigen Brüder
Welcome,         Profile    Billing    Logout  
 0 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Meran, Johannes
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
Derre, Tine
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
NALPAC, NCT05472259 / 2020-003889-39: A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC

Recruiting
2
134
Europe
Nanoliposomal irinotecan, Onyvide, 5 FU, Fluorouracil, Leucovorin, Folinate, Elvorine, Oxaliplatin
Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels
Metastatic Pancreatic Ductal Adenocarcinoma
06/25
12/27
OPTIMIZE-1, NCT04888312: Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

Active, not recruiting
1/2
94
Europe
CD40 agonist mitazalimab in combination with chemotherapy, ADC-1013, JNJ-64457107
Alligator Bioscience AB, Theradex, 4Pharma Ltd.
Metastatic Pancreatic Ductal Adenocarcinoma
02/25
06/25
Dermine, Alexandre
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
STEREOPAC, NCT05083247: Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Recruiting
2
256
Europe
mFOLFIRINOX or Gemcitabine nab-paclitaxel, mFFX or Gem/Nab-p, Isotoxic High-Dose (iHD)-SBRT, Surgery
Erasme University Hospital, Jules Bordet Institute, Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels
Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
12/27
12/30
SHAPERS, NCT06052332: Efficacy and Safety of SCRT Versus TNT in Older Patients With Locally Advanced Rectal Cancer

Recruiting
N/A
230
Europe
Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision, Total neoadjuvant therapy
Jules Bordet Institute
Locally Advanced Rectal Cancer, Older People
12/29
12/33
Mineur, Géraldine
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
Dujardin, Esther
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27

Download Options